Shares dropped after the company issued a more cautious outlook on top-line growth for 2026, citing challenging conditions in Germany and supply constraints for biosimilar drugs.
Swiss generic drugmaker Sandoz on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply constraints weighed on
mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab biosimilar candidate. Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases.
Sandoz CEO Richard Saynor warned U.S. patients could ultimately bear the cost of threatened tariffs on imported generic drugs. Saynor said manufacturers facing steep tariffs could be forced to raise prices or stop supplying some medicines.
Sandoz aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its focus from generics to biosimilars.
Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million The collaboration further expands the parties' 2025 oncology biosimilars partnership ...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.